EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

XIIlab Co. Ltd. (189330) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of XIIlab Co. Ltd. KRW 2,120, price KRW 11,240, upside -81.1%, quality 36 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Technology · KR

XC Thin data Sep 24, 2026

XIIlab Co. Ltd.

189330 · KQ

Weakest SetupStrongly overvalued and low quality.

!Fair value 2,120 KRW · Strongly overvalued (−81%)
!Quality 36/100
!Weak Growth (revenue 5y −1.6 %/yr)
!Loss-making · -38.1% net margin (TTM)
!negative free cash flow
!Trails peers (1/7)
!Narrow moat 9/100
!Insider activity 45/100
!Evidence only low, so the estimate is less certain
Watch XIIlab Co. Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

60,734 KRW 3,475 KRW Fair Value 2,120 KRW May 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 3,475 KRW – 60,734 KRW · fair‑value band 1,400 KRW – 2,651 KRW · the 11,240 KRW price screens above the 2,120 KRW fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow XIIlab Co. in your weekly email

Every Wednesday you see whether XIIlab Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

XIIlab Co.,Ltd provides data-driven AI video analysis services in South Korea. It offers X-AIVA, an AI video analysis platform; Uyuni, an AI standard platform based on Kubenetes; X-Labeller, a video data processing solution; X-GEN, a synthetic data generation solution; and Vidigo, a cloud-based AI video and speech analysis service.

Show more

XIIlab Co.,Ltd provides data-driven AI video analysis services in South Korea. It offers X-AIVA, an AI video analysis platform; Uyuni, an AI standard platform based on Kubenetes; X-Labeller, a video data processing solution; X-GEN, a synthetic data generation solution; and Vidigo, a cloud-based AI video and speech analysis service. The company was founded in 2010 and is headquartered in Seoul, South Korea.

Stock analysis

XIIlab Co. Ltd. (189330) currently trades at 11,240 KRW, while our model-based Fair Value estimate is 2,120 KRW, implying the stock looks roughly 429.9% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 1,400 KRW (bear) to 2,651 KRW (bull), the price of 11,240 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Technology sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

XIIlab Co. Ltd. reported revenue of 10.3B KRW in FY2025 versus 5.8B KRW in FY2021, a compound +15.5%/yr. Reported net income was −3.1B KRW in FY2025.

Key figures

Market cap 105B KRW (≈ $73.8M) · P/S ratio 7.81 · Net margin −30.4% · Return on equity −25.1% · Return on assets (EBIT) −22.4% · Operating margin −173% · Revenue (TTM) 10.6B KRW · Revenue growth (YoY) +41.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).

What moves the price

The share trades about 38% below its 52-week high and 223% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Technology peers we cover trades at 66% fair-value upside, at −81%, 189330 screens richer than that median.

Fair Value models

Bear 1,400 KRW Fair Value 2,120 KRW Bull 2,651 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 1,339 KRW 1,794 KRW 2,678 KRW 51
All 1 models by family
Asset-Based
NCAV (Graham) 1,339 KRW 1,794 KRW 2,678 KRW 51

Open the full fair value analysis →

Notify me when 189330 reaches fair value

Put 189330 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 36/100

Of which business quality 39 · Market factors (momentum, volatility) 68

Profitability 7
Margins and returns on capital today
Quality Growth 65
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 98
Balance sheet, leverage, solvency risk
Investment 79
Disciplined investing over empire-building
Low Volatility 16
Calm price path (market factor)
Momentum 99
Price trend over the last 3–12 months (market factor)
52W Momentum 76
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 7/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+13.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.6%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
6.3% (2020) → −31.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

189330 screens 430% overvalued. Compare with International Business Machines Corporation →

Compare XIIlab Co. Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Information Technology Services · 490 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 39 · Bottom 25%
Fair Value upside −81% · Bottom 25%
Profitability
Return on assets −14% · Bottom 25%
Net margin (TTM) −38% · Bottom 25%
Operating margin (TTM) −173% · Bottom 25%
Growth and dividend
Revenue growth 42% · Top 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 44
FUTURE (revenue growth)100 · sector 31
PAST (return on equity)0 · sector 36
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 43

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Information Technology Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
International Business Machines Corporation IBM $231.38 $188.22 −19%
Accenture plc ACN $183.72 $305.06 +66%
Tata Consultancy Services Limited TCS ₹2,090 ₹2,993 +43%
Infosys Limited INFY ₹1,021 ₹1,690 +66%
HCL Technologies Limited HCLTECH ₹1,257 ₹1,926 +53%
Fidelity National Information Services, Inc FIS $34.96 $32.47 −7%
Cognizant Technology Solutions Corporation CTSH $58.68 $132.01 +125%
Wipro Limited WIPRO ₹164.90 ₹287.90 +75%
Capgemini SE CAP €106.30 €223.90 +111%
CDW Corporation CDW $147.43 $162.00 +10%

Explore undervalued stocks

More undervalued Technology stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

XIIlab Co. Ltd. · Fair Value
2,120 KRW −430%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "XIIlab Co. Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/189330

Frequently asked questions

Is XIIlab Co. Ltd. (189330) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 2,120 KRW versus a price of 11,240 KRW, about −81% upside (overvalued).
What is the fair value of 189330?
Our model-based fair value for XIIlab Co. Ltd. is 2,120 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 11,240 KRW.
What is the quality score of 189330?
XIIlab Co. Ltd. has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for XIIlab Co. Ltd. (189330)?
Our model-based price target is the fair value of 2,120 KRW (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 1,400 KRW, optimistic scenario 2,651 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the XIIlab Co. Ltd. stock forecast for 2026?
Our models put fair value at 2,120 KRW, about −81% upside versus a price of 11,240 KRW (overvalued). Cautious scenario 1,400 KRW, optimistic scenario 2,651 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of XIIlab Co. Ltd. (189330)?
XIIlab Co. Ltd. reported trailing-twelve-month revenue of about 10.6B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of XIIlab Co. Ltd. (189330)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For XIIlab Co. Ltd. it is 2,120 KRW per share (as of Sep 24, 2026), against a price of 11,240 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is XIIlab Co. Ltd. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 189330 trades above its calculated fair value: price 11,240 KRW, fair value 2,120 KRW, a gap of about −81% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 189330?
No. The price is what the market pays today (11,240 KRW); the fair value is what the company's own numbers justify (2,120 KRW). For XIIlab Co. Ltd. the two are 9,120 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is XIIlab Co. Ltd. worth?
The market values XIIlab Co. Ltd. at about 105B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 11,240 KRW; our models calculate a fair value of 2,120 KRW per share.
What do the bullish and bearish scenarios say about 189330?
Our models span a range for XIIlab Co. Ltd.: cautious scenario 1,400 KRW, base 2,120 KRW, optimistic 2,651 KRW per share (as of Sep 24, 2026, price 11,240 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of XIIlab Co. Ltd. (189330)?
Balance-sheet figures for XIIlab Co. Ltd. (as of Sep 24, 2026): return on equity −25.1%. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is 189330 from its 52-week high?
XIIlab Co. Ltd. trades at 11,240 KRW, about 38% below its 52-week high of 18,180 KRW and 223% above the low of 3,475 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 2,120 KRW is for.
Which stocks are comparable to XIIlab Co. Ltd.?
From the same area (Technology) we also value International Business Machines Corporation, Accenture plc, Tata Consultancy Services Limited, Infosys Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is XIIlab Co. Ltd. stock attractive at the current price?
The data as of Sep 24, 2026: price 11,240 KRW, calculated fair value 2,120 KRW (−81%), Quality Score 36/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 189330 calculated?
We run XIIlab Co. Ltd. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 2,120 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. XIIlab Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of XIIlab Co. Ltd. (189330)?
The closing price on Sep 23, 2026 was 11,240 KRW. Our model-based fair value is 2,120 KRW, about −81% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with XIIlab Co. Ltd. right now?
The price sits above even our optimistic bull case (2,651 KRW). The favourable scenario is already priced in. Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (1,400 KRW to 2,651 KRW) leaves room in how you read the outcome.

Key figures of XIIlab Co. Ltd.

How large is the market capitalisation of XIIlab Co. Ltd. (189330)?
The market capitalisation of XIIlab Co. Ltd. is 105B KRW (≈ $73.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of XIIlab Co. Ltd. (189330)?
The price-to-sales ratio of XIIlab Co. Ltd. is 7.81 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of XIIlab Co. Ltd. (189330)?
The net margin of XIIlab Co. Ltd. is −30.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of XIIlab Co. Ltd. (189330)?
The return on equity (ROE) of XIIlab Co. Ltd. is −25.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of XIIlab Co. Ltd. (189330)?
On an EBIT basis the return on assets of XIIlab Co. Ltd. is −22.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of XIIlab Co. Ltd. (189330)?
The operating margin of XIIlab Co. Ltd. is −173% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at XIIlab Co. Ltd. (189330)?
Revenue at XIIlab Co. Ltd. is growing +41.8% versus a year earlier (3y avg +1.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does XIIlab Co. Ltd. (189330) generate?
The free cash flow of XIIlab Co. Ltd. is −1.4B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch XIIlab Co. Ltd. in the live analysis

One click puts XIIlab Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.